Dana-Farber Cancer Institute account plan
Expert compassionate cancer care
At a glance
Dana-Farber Cancer Institute is a Boston not-for-profit cancer research and treatment center with FY2025 operating revenues of $3,922,850 thousand.
Dana-Farber Cancer Institute is a comprehensive cancer center for basic and clinical cancer research and treatment, a Massachusetts not-for-profit 501(c)(3) that primarily serves patients in the New England region. It earns revenue from patient care, research (grants, contracts, licenses and research gifts) and philanthropy; its inpatient hospital currently sits inside Brigham & Women's Hospital. In FY2025 (year ended September 30, 2025) total operating revenues were $3,922,850 thousand against $3,438,436 thousand in FY2024, with operating income of $102,353 thousand. It is building its own 300-bed cancer hospital in the Longwood Medical Area. Benjamin L. Ebert is President and CEO.
Business units
Patient care
about 77% of FY2025 operating revenues ($3,012,853 thousand)Outpatient and inpatient cancer care, with inpatient care delivered inside Brigham & Women's Hospital. Net patient service revenue rose from $2,593,981 thousand in FY2024; Medicare was 37% of the payor mix and HMO, commercial and other 36%.
Research
about 18% of FY2025 operating revenues ($706,681 thousand)Basic and clinical cancer research funded by federal grants ($229,899 thousand), non-federal grants ($231,733 thousand), gifts and licenses and royalties. Federal award expenditures were $230,341,899, mostly from HHS/NIH.
Philanthropy
about 4% of FY2025 operating revenues ($147,239 thousand)Unrestricted contributions and bequests; total contributions received and pledged were $314,121 thousand, of which the Jimmy Fund raised $117,696 thousand.
Other operating revenues
about 1% of FY2025 operating revenues ($56,077 thousand)Management services, rent, royalties and ancillary services such as parking, cafeteria and gift shop.
Strategic priorities
- New 300-bed cancer hospital
- A 300-bed cancer hospital in the Longwood Medical Area, owned and operated by Dana-Farber, received final Massachusetts DPH approval on May 19, 2025; its debt financing is expected in 2026.
- Clinical collaboration with BIDMC
- The hospital is central to a clinical collaboration with Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians for adult cancer patients.
- Protect research funding
- About one-third of research funding comes from the federal government; the CEO has been engaging Congress, citing bipartisan support for cancer research.
- AI in care and research
- AI is to take care of administrative tasks, improve diagnostic accuracy in radiology and pathology, and transform translational research with large language models.
- Scientific bets
- Early detection and interception, drugs against "undruggable" targets such as KRAS, and extra support for rare and pediatric cancers.
Investments and deals
- Hospital construction
- Additions to property, plant and equipment were $165,584 thousand in FY2025 and construction-in-progress rose to $206,229 thousand.
- Hospital financing hedges
- Swaptions with notional amounts of $1,191,644 thousand with JPMorgan and $611,094 thousand with Goldman Sachs hedge the anticipated hospital debt financing.
- Global oncology
- Dana-Farber Global Oncology is the entity through which the Institute is engaging in work in China.
Challenges and risks
- Federal research funding uncertainty
- Federal funding freezes hit Harvard University and Harvard Medical School; Dana-Farber says it had suffered no cuts but is preparing for various scenarios.
- Complex reimbursement rules
- Medicare and Medicaid rules are complex and subject to interpretation, so recorded estimates may change by a material amount.
- Interest rate and investment risk
- Variable-rate bonds, swaps and swaptions carry interest rate risk, and $1,759,967 thousand sits in non-marketable hedge and private equity funds.
- Grant competition
- Less than 10 percent of the grants Dana-Farber submits to the National Cancer Institute are funded.
What leadership says
“The promise that AI can accelerate the development of new cancer drugs and accelerate scientific research broadly is absolutely thrilling.”
“AI in oncology isn't a way of replacing humans. It's a way of taking care of some of the administrative tasks that allow us to have more human interactions with our patients.”
“I'm an absolute believer that this is the most promising time for cancer research and for new therapeutics for cancer that we've ever had.”
Where a supplier can help
- New hospital fit-out
- The 300-bed Longwood hospital, with construction-in-progress already rising, creates demand for medical equipment, IT infrastructure and facility services.
- AI for radiology, pathology and admin
- The CEO's AI priorities (administrative tasks, diagnostic accuracy, large language models in translational research) fit clinical AI and data platform vendors.
- Research operations and grants management
- With research funded by federal grants, non-federal grants and gifts, and federal funding uncertain, grant management and research administration tools can help.
- Clinical trial partnerships
- Pharma and biotech fund part of the research through clinical trials, which suits trial sponsors and clinical research service providers.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Dana-Farber Cancer Institute?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Dana-Farber Cancer Institute, Inc. and Subsidiaries - Audited Consolidated Financial Statements and Uniform Guidance Reports, Year ended September 30, 2025
- Dana-Farber Cancer Institute, Inc. is a comprehensive cancer center for basic and clinical cancer research and treatment, a Massachusetts not-for-profit 501(c)(3) that primarily serves patients in the New England region; its inpatient hospital currently sits inside Brigham & Women's Hospital.
- FY2025 (year ended September 30, 2025) total operating revenues were $3,922,850 thousand vs $3,438,436 thousand in FY2024; net patient service revenue $3,012,853 thousand (FY2024: $2,593,981 thousand), research revenues $706,681 thousand.
- Operating income was $102,353 thousand (FY2024: $87,031 thousand); with $236,617 thousand of non-operating gains the excess of revenues over expenses reached $338,970 thousand.
- Balance sheet: total assets $5,994,076 thousand, investments $3,554,754 thousand, total net assets $4,485,156 thousand, long-term debt and finance leases $537,541 thousand before current portion; three $100,000 thousand credit lines undrawn.
- Payor mix of patient revenue: Medicare 37%, HMO/commercial/other 36%, Blue Cross 22%, Medicaid 4%, self-pay 1%.
- Research is funded by federal grants ($229,899 thousand), non-federal grants ($231,733 thousand), gifts ($205,873 thousand) and licenses/royalties ($39,176 thousand); total federal award expenditures were $230,341,899, mostly HHS/NIH.
- Strategy: a 300-bed cancer inpatient hospital in the Longwood Medical Area, owned and operated by Dana-Farber, approved by the Massachusetts DPH on May 19, 2025, central to a clinical collaboration with Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians; its debt financing is expected in 2026 and is hedged with swaptions (notional $1,191,644 thousand with JPMorgan and $611,094 thousand with Goldman Sachs).
- Capex: additions to property, plant and equipment $165,584 thousand in FY2025; construction-in-progress rose to $206,229 thousand.
- Clean audit by KPMG (report dated January 21, 2026): unmodified opinion, no material weaknesses, no findings, low-risk auditee.
- Risks named: complex Medicare/Medicaid regulation and possible government review, non-marketable alternative investments ($1,759,967 thousand in hedge and private equity funds), interest-rate risk on variable-rate debt and swaptions, malpractice and litigation.
- In Celebration of a Decades-Long Journey of Discovery and Innovation (The ASCO Post interview with Benjamin L. Ebert)
- Benjamin L. Ebert, MD, PhD, marked one year as President and CEO of Dana-Farber Cancer Institute; he also directs Dana-Farber/Harvard Cancer Center and chaired Medical Oncology at Dana-Farber from 2017 to 2024.
- The interviewer frames the period around Dana-Farber's new collaboration with Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians.
- On federal research funding: he has been "spending a bit of time in Washington" and is impressed by "the bipartisan support there is for biomedical research, particularly in cancer research."
- He welcomes Dana-Farber's Anthony Letai becoming the 18th Director of the National Cancer Institute on September 29, 2025.
- On AI: it takes care of administrative tasks, will improve diagnostic accuracy in radiology and pathology, and can transform translational research with large language models; "The promise that AI can accelerate the development of new cancer drugs and accelerate scientific research broadly is absolutely thrilling."
- His science background: myelodysplastic syndromes, clonal hematopoiesis and the mechanism of lenalidomide, which fed the field of targeted protein degradation.
- Leadership focus as chair and now CEO: hiring collaborative people and cultivating the right environment for discovery and clinical medicine.
- Walker Webcast: Rewriting the Rules of Medicine with Dr. Ben Ebert, President and CEO of Dana-Farber Cancer Institute
- Benjamin Ebert, President and CEO of Dana-Farber, on the Walker Webcast with Willy Walker (April 30, 2025).
- Dana-Farber is building its own inpatient hospital of 300 beds, capped in height by a nearby park on the Muddy River.
- Budget: "$3 billion budget, $3.5 billion budget? Much of that is the clinical budget"; research funding is about one-third federal (NIH/NCI), a little more than a third philanthropy, the rest private sector (pharma, biotech, venture).
- At the National Cancer Institute "less than 10 percent of the grants that we submit are actually funded"; philanthropy lets projects start quickly.
- Federal freezes had hit Harvard University and Harvard Medical School but not the affiliate hospitals; Dana-Farber has "independent governance and independent finances" and had suffered no cuts to date while preparing for scenarios.
- The Pan-Mass Challenge raised $75 million last year; 6,000-7,000 riders.
- Talent: culture and the Boston ecosystem attract recruits more than pay; collaboration through Break Through Cancer with MD Anderson, Memorial Sloan Kettering, MIT and Johns Hopkins.
- Bets: AI (AlphaFold, AI in radiology and pathology), early detection and interception (blood biopsies), drugs against "undruggable" targets such as KRAS, and over-allocation to rare and pediatric cancers.
Questions about Dana-Farber Cancer Institute
What does Dana-Farber Cancer Institute do?
It is a comprehensive cancer center in Boston dedicated to basic and clinical cancer research and treatment, primarily serving patients in New England.
What is Dana-Farber's revenue?
Total operating revenues were $3,922,850 thousand in FY2025 (year ended September 30, 2025), of which net patient service revenue was $3,012,853 thousand.
Who leads Dana-Farber?
Benjamin L. Ebert, MD, PhD, is President and CEO; he also directs Dana-Farber/Harvard Cancer Center.
What is Dana-Farber's strategy?
Building its own 300-bed cancer hospital in the Longwood Medical Area as part of a clinical collaboration with Beth Israel Deaconess Medical Center, while investing in AI, early detection and new therapies.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)